Education
About Us
Working with TipRanks
Follow Us
Sensus Healthcare (SRTS)
NASDAQ:SRTS
Earnings Data
Report Date
Jul 31, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.01Last Year’s EPS
0.1Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 15, 2025
|% Change Since: 0.64%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook for Sensus Healthcare. While there were significant highlights such as the expansion of the FDA program and increased brand visibility, the company faced challenges with a revenue decline and increased operating expenses leading to a net loss for the quarter. However, there is optimism for the remainder of 2025 with expected revenue growth from the FDA program and international expansion.Company Guidance
During the Sensus Healthcare Q1 2025 earnings call, the company reported first-quarter revenues of $8.3 million, a decrease from $10.7 million in Q1 2024, primarily due to reduced unit sales to a major customer. Despite a net loss of $2.6 million or $0.16 per share, the company outlined significant investments in sales, marketing, and R&D, with operating expenses rising to $2.2 million in G&A and $2.6 million in R&D. Sensus shipped 21 SRT systems during the quarter, increasing its installed base to over 880 units, with expectations to surpass 900 by Q2 and reach 1,000 within a year. The company highlighted a 65% increase in patient treatments from its fair deal agreements, underscoring anticipated contributions to revenue in the second half of 2025. Adjusted EBITDA was negative $2.5 million, with the company maintaining a strong cash position of $19.1 million and no debt. Sensus is optimistic about returning to profitability in the upcoming quarters as its fair deal agreements mature and contribute more significantly to revenue.Expansion of Fair Deal Agreement Program
The Fair Deal Agreement (FDA) program showed a 65% increase in patient treatments from Q4 2024 to Q1 2025. This program is expected to significantly contribute to revenue in the second half of 2025, with plans to sign 3-5 additional multi-site FDA customers in 2025.
Strong Marketing and Brand Visibility
Sensus Healthcare expanded its brand visibility through participation in major industry events and targeted marketing activities, leading to a strong pipeline of new FDA opportunities.
International Expansion and Product Innovation
The company is progressing in its international strategy, attending major conferences such as ESTRO in Vienna and is set to exhibit at the Australian Academy of Dermatology Annual Meeting. Additionally, enhancements to the transdermal infusion system (TDI) are underway, with an expected FDA determination by year-end.
SRTS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
SRTS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 15, 2025 | $4.66 | $4.46 | -4.29% |
Feb 05, 2025 | $8.99 | $6.08 | -32.37% |
Nov 14, 2024 | $7.29 | $7.64 | +4.80% |
Aug 08, 2024 | $6.30 | $6.39 | +1.43% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Sensus Healthcare (SRTS) report earnings?
Sensus Healthcare (SRTS) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
What is Sensus Healthcare (SRTS) earnings time?
Sensus Healthcare (SRTS) earnings time is at Jul 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SRTS EPS forecast?
SRTS EPS forecast for the fiscal quarter 2025 (Q2) is 0.01.